Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
Move strengthens footprint in Western India and expands multi-specialty care network
The study is a global, randomized, double-blind, placebo-controlled trial testing GLM101 for phosphomannomutase 2 congenital disorder of glycosylation
The drug meets all primary endpoints across 608 patients in Europe and India, strengthening the company's biosimilars pipeline
The move leverages Novartis’ deep expertise in IgE biology and long-standing presence in allergic disease treatments
Marks significant milestone for breakthrough biologic to treat rare blood cancers
New partnership combines Shilpa Biologicals’ development and manufacturing capabilities with SteinCares’ regional commercialization platform
This license is a key regulatory milestone in advancing Hester's prevention-led poultry healthcare portfolio
InflaRx is streamlining operations and largely discontinuing non-essential activities outside izicopan’s development
Astal estimates the collaboration will generate incremental revenue of approximately Rs. 300 crore upon implementation
Subscribe To Our Newsletter & Stay Updated
